Coronavirus information from UCLA and UCLA Health.
  

Avesta76 is focused on a target that has the potential to treat every type of tumor.

Market:

Avesta76's therapies will address the need for safe and effective treatments across multiple cancers. This is a market with 17 million annual diagnoses, 10 million deaths, and over $150B spent on drugs per year. The company's initial focus is on ovarian cancer, a $5.9B market growing by 7% annually with over 21,000 new cases and 13,000 deaths in the U.S. each year.

Technology:

Avesta76’s drug target has been thoroughly validated through preclinical research in cells and animal models, and has the potential to act as a cancer “masterswitch.” By inhibiting the target, the company’s therapies disrupt the normal function of a biochemical pathway that cancer needs in order to grow, safely spurring remission and preventing the formation of new tumors in peer-reviewed studies. Both small-molecule drugs and monoclonal antibodies are under development.

Advantages:

  • Unique drug target
  • Fundamentally disrupts necessary cancer pathways
  • Effective across all cancer types
  • No observed adverse effects Multiple drug candidates

Development Stage:

  • Pre-clinical

Patents Issued:

  • Coming Soon

Select Publications:

  • Rlip depletion prevents spontaneous neoplasia in TP53 null mice (https://pubmed.ncbi.nlm.nih.gov/29572430/)
  • Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis (https://pubmed.ncbi.nlm.nih.gov/33445456/)
  • Rlip Depletion Suppresses Growth of Breast Cancer (https://pubmed.ncbi.nlm.nih.gov/32498332/)

Contact:

Website: www.avesta76.com
Phone: 512-796-1982
Email: akash@avesta76.com
LinkedIn